Cancel
Candel Therapeutics
Candel Therapeutics Employees
7 people indexed:
-
78bwpqi.9i820p@436843u0.w7z Sign up to see email
-
43i6uk3i2.y3wyi5@j5v1pkhh.1gi Sign up to see email
-
z9913.b7g376@20v18ugu.ggz Sign up to see email
-
0sf3.473@q57s8g1i.fs2 Sign up to see email
-
Seshu Tyagarajan
Chief Technical and Development Officer
zfbw8.6ivz6q89i1@085q81q7.ib2 Sign up to see emailw9844.61w1qv0406@01ib8iw0.b88 Sign up to see email -
qj9jf.3bvq5kp@49pi9q4z.ikg Sign up to see email
-
3v6wv05.9fjpwyj@6w5b9wk8.13q Sign up to see email
Candel Therapeutics Company Information
Candel Therapeutics, headquartered in Needham, Massachusetts, specializes in the development of viral immunotherapies aimed at enhancing the immune system’s ability to combat various cancers. The company’s investigational therapies are designed to generate a personalized immune response, tailored specifically to the patient’s cancer, potentially offering long-lasting protection. These therapies are being developed with a focus on maintaining favorable benefit-to-risk profiles. Candel Therapeutics is actively conducting clinical trials targeting diseases such as prostate cancer, brain cancer, pancreatic cancer, and lung cancer. A notable aspect of their clinical development is a phase 3 randomized controlled trial of CAN-2409 followed by valacyclovir in conjunction with standard radiation therapy for patients with localized intermediate or high-risk prostate cancer. The company’s portfolio includes CAN-2409, an off-the-shelf adenovirus-based therapy, and CAN-3110, a tumor-specific oncolytic virus derived from the herpes simplex virus. Additionally, Candel utilizes its proprietary EnLIGHTEN™ Discovery Platform to innovate and develop new viral immunotherapies for solid tumors.
Report inaccurate information
Report inaccurate information
